Follow Tilray Brands to never miss an important update.
Tilray reported record first-quarter revenue of $257 million, a 23 percent jump from last year. The growth was led by its beverage business, which brought in $101 million, and a 71 percent surge in its European and Middle Eastern markets. The company also improved its gross margin, the percentage of revenue left after paying for the goods sold, to 30 percent and paid down $42 million in debt.
Despite the sales growth, the company lost 32 cents per share, which was wider than the 18-cent loss analysts expected. This highlights the ongoing challenge of turning high sales growth into actual profit. For long-term owners, the takeaway is that the pivot into alcohol and international medical cannabis is working to diversify the business, but the path to consistent profitability remains the main hurdle. The stock fell about 5 percent following the report.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
German health authorities issued new guidance that makes it easier for doctors to prescribe full-spectrum cannabis extracts. This move provides a clearer framework for medical professionals and helps ensure patients can more reliably access these treatments.
This is a helpful development for Tilray because Germany is a cornerstone of its international growth plan. As the company works to offset slow growth in the Canadian market, it relies on European medical sales to drive higher profits. Clearer rules for doctors generally lead to more consistent prescribing and higher sales volumes over time.
Source: GlobeNewsWire
Management has missed its profit targets for four straight quarters. This suggests the business is still too unpredictable for leaders to accurately forecast as they pivot from cannabis into beer.
| Expectation | |
|---|---|
| EPS | $-0.18 |
| Revenue | $266M |
Follow Tilray Brands to get the latest and most important updates.
Follow TLRY